Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Recruiting now · Phase 2

Conditions studied: Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases

In brief

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Key facts

Study ID

NCT06758700

Run by

Shanghai Pulmonary Hospital, Shanghai, China

People needed

15

Starts

2025-02-07

Expected to finish

2026-12-31

Last updated by the study team

2025-12-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• extensive stage small cell lung cancer
• Progression after receiving at least one chemotherapy drug treatment in the past;
• ECOG score 0-1
• c-Myc-driven
• Expected survival period ≥3 months
• Age: 18-75 years old;
• The informed consent form complies with the ICH-GCP principles.

You may not qualify if…

• No measurable lesions
• Other severe and persistent diseases or organ system dysfunction;
• Women planning pregnancy or men planning family planning;
• Women who are pregnant or breastfeeding;
• Those who cannot follow the research protocol provided by the investigator.

Where it is running

• Shanghai Pulmonary Hospital, Shanghai, China — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.